Combined Detection Reagent Of Troponin I,Myoglobin And Creatine
Kinase Isoenzyme Performance Index
CTnI/MYO/CK-MB Overview
The troponin I/ myoglobin/creatine kinase isoenzyme (cTnI/ Myo
/CK-MB) includes the following three indicators: The combined
detection of troponin I (cTnI), myoglobin (Myo) and creatine kinase
isoenzyme (CK-MB) is of great significance in the early diagnosis
of acute myocardial diseases such as AMI
American Academy of Clinical Biochemistry (NACB) practice
guidelines
All suspected patients with ACS should be tested for markers of
myocardial necrosis
Troponin is the primary marker for the diagnosis of myocardial
infarction
Myoglobin in combination with specific markers of myocardial
necrosis, such as cTnI/CK-MB, may help to rule out or diagnose
myocardial infarction more quickly
| MYO | CK-MB | cTnI |
| molecular weight | 17.8KD | 86KD | 22.5KD |
| Rise time | 1-2h | 4-6h | 3-6h |
| Peak time | 6-9h | 24h | 12-16h |
| recovery time | 18-30h | 2-3d | 4-10d |
| Clinical value | 1. The most important index of AMI was excluded in the early stage 2. Recurrent diagnosis of AMI, and the best evaluation index of
reperfusion treatment effect | 1. Estimate infarct size or reinfarct 2. The most valuable non-ST segment elevation marker of MI | 1. Preferred markers for the diagnosis of AMI 2. Judge the infarct size and risk stratification |
cTnI/MYO/CK-MB Performance Index
| Detection range | sample size | Sample type | Test time |
| cTnI | MYO | CK-MB | 60μl | Whole blood / serum / plasma | 15min |
| 0.1~50ng/mL | 10~200ng/mL | 0.8~100ng/mL |
CTnI/MYO/CK-MB Clinical Significance
- It is helpful for early diagnosis and risk stratification of acute
coronary syndrome
- Determine the area of myocardial ischemia injury
- Differential diagnosis of various causes of chest pain
- Monitoring of myocardial injury caused by various causes
- Evaluation of the clinical efficacy of certain therapeutic agents
| Possibility of outcome | |
| cTnI | CK-MB | MYO | Clinical possibility |
+ | + | + | Myocardial infarction/myocardial injury can be diagnosed basically,
and the occurrence time is 12-24 hours; |
| + | + | - | It can be basically diagnosed as myocardial infarction/myocardial
injury, and the detection time is more than 1 day, which has passed
the detection window period of Myo. |
| + | - | - | Myocardial infarction/myocardial injury has occurred for 2-3 days,
and it is recommended to check again several hours later. |
| + | - | + | In patients with myocardial infarction/myocardial injury, the
detection time may be longer than 3 days for symptoms, and patients
suffer from reinjury or infarction size enlargement; |
| - | + | + | Early myocardial infarction/myocardial injury/muscle injury, cTnI
reexamination is recommended within 4-8 hours; |
- | - | + | 1. Early myocardial infarction/myocardial injury, cTnI
reexamination is recommended within 4-8 hours; |
| 2. It may be caused by other injury diseases, such as creative
work, skeletal muscle injury, liver and kidney disease; |
| - | + | - | 1. For minor myocardial injury, it is recommended to reexamine cTnI
within 4-8 hours; |
| 2. It may be non-myocardial injury disease, and the detection time
has passed the Myo window period; |
- | - | - | Myocardial infarction/myocardial injury is basically ruled out. If
highly suspected, it is recommended to check every 2 to 4 hours. |
Application Department
Outpatient, emergency, physical examination center, cardiovascular,
ICU, chest pain center and other departments
CTnI/MYO/CK-MB Clinical Comparison
Company profile
Zhongxiu Science And Technology Co.,Ltd., is a high-tech enterprise
engaged in the research and development, production and operation
of in vitro diagnostic products. The in vitro diagnostic products
developed by the company cover POCT series, microbial series,
biochemical series and immune series reagents and supporting
instruments.
The company has always adhered to the core concept of "fast and
accurate, living up to life", committed to providing society with
excellent products and services, and contributing to the cause of
human health.
